Clinical Trial Update: An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating autologous CD34+ hematopoietic progenitor cells transduced with OZ1 versus placebo in HIV infection to assess efficacy and safety. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• OZ1 (anti-HIV-1 ribozyme OZ1)

Snippet

Sponsor: Janssen-Cilag Pty Ltd | Conditions: HIV-1 | Phase 2 | Status: COMPLETED